Effects of SLCO1B1 Polymorphism and Pitavastatin on the Pharmacokinetics of Repaglinide in Chinese Healthy Volunteers.
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Pitavastatin (Primary) ; Repaglinide (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Type 2 diabetes mellitus
- Focus Pharmacogenomic; Pharmacokinetics
- 21 May 2012 Actual end date changed from Feb 2009 to Nov 2009 as reported by Chinese Clinical Trial Register record.
- 28 Dec 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12611001254987).
- 06 Dec 2011 New trial record